Who are Tc99m sestamibi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Technetium Tc99m Sestamibi, Technetium Tc99m Tetrofosmin injections.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tc99m-sestamibi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tc99m sestamibi — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tc99m sestamibi (Tc99m sestamibi) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiotracer / Diagnostic imaging agent. Area: Cardiology / Nuclear Medicine.

marketed Radiotracer / Diagnostic imaging agent Mitochondrial membrane potential Cardiology / Nuclear Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Tc99m sestamibi (Tc99m sestamibi) — M.D. Anderson Cancer Center. Tc-99m sestamibi is a radiotracer that accumulates in mitochondria of viable cells, allowing visualization of myocardial perfusion and detection of ischemia via nuclear imaging.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tc99m sestamibi TARGET	Tc99m sestamibi	M.D. Anderson Cancer Center	marketed	Radiotracer / Diagnostic imaging agent	Mitochondrial membrane potential
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Technetium Tc99m Tetrofosmin injections	Technetium Tc99m Tetrofosmin injections	GE Healthcare	marketed	Myocardial perfusion imaging agent	Mitochondrial membrane potential in myocardial cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiotracer / Diagnostic imaging agent class)

M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tc99m sestamibi — Competitive Intelligence Brief. https://druglandscape.com/ci/tc99m-sestamibi. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing